03rd week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090016941 | Electrode Device For Plasma Discharge - It is disclosed a plasma discharging electrode device generating non-equilibrium plasma for treating a gas. The device has a substrate comprising an integrated sintered ceramic body; an electrode embedded in said substrate; and a catalyst supported by said substrate and accelerating the reaction of the gas. The substrate has a surface portion whose porosity is higher than that of a portion in the vicinity of the electrode in the substrate. | 2009-01-15 |
20090016942 | OZONE INFECTION CONTROL DEVICE - An ozone infection control device includes a body portion having a channel or passageway for receiving a catheter so that the catheter may extend from outwardly of the device to a catheter exit site at a central area of the device. A plurality of air inlet openings are spaced around a peripheral skirt of the device. A negative ion ozone generator having a plurality of spaced pointed projections is located within the body portion inwardly of the peripheral skirt and in the path of flow of air flowing through the inlet openings to generate ozone from the air. An oppositely charged ground disk is mounted within the body portion inwardly of the ozone generator. Air flows along a path of flow from the inlet openings to the ozone generator where ozone is created. The path of flow then extends to the ground disk and to the catheter exit site to bathe the catheter exit site with anti-microbial ozone. The flow path would then exit from the device through the catheter passageway. | 2009-01-15 |
20090016943 | Flexible Mixing Surface - An apparatus for mixing a compound that hardens when cured, the apparatus allowing for rapid removal of the compound after hardening. A mixing pad is a thick, flexible sheet that has anti-adhesion properties. The mixing pad is supported by a support device that has a rigid support surface that maintains the planar configuration of the work surface of the pad. The support device includes means for securing the mixing pad to a support surface of the device. In one embodiment, the support device includes a compartment for storing the mixing pad. The compartment is also configured for being a mold to form the pad. In another embodiment, the support device has a support surface with protrusions that engage openings in the pad, thereby securing the pad to the support device. | 2009-01-15 |
20090016944 | Hydrogen generator, Carbon dioxide and sulfate captor - This invention provides a means to produce on site Hydrogen to power fuel cells or Hydrogen engines storing the energy in Calcium metal. It continues by using the Calcium hydroxide byproduct of Calcium generated Hydrogen reaction to capture Carbon dioxide from exhaust situations, both moving and stationary as trucks and power plants. This reaction goes to completion with the sedimentation of Calcium carbonate, which may be useful to the cement industry as a component of their products, or it could be used to capture sulfates in stack gas. Either Calcium carbonate or Calcium sulfate may be electrolyzed to recover metallic Calcium, which is not readily available on the market at this time. Solar power, water wheels, resistive gym apparatus, wind power generation of electrical energy as well as unused power from power plants can electrolyze water into Hydrogen and Oxygen. The Hydrogen is passed through and over Calcium carbonate freeing the Calcium as pure metal and releasing as gases water and Carbon dioxide, which, if fed into a greenhouse, will make plants grow rapidly and during daylight, release heavily Oxygenated air from the greenhouse environment. Oxygen can be sold to health, scuba and industrial businesses. These reactions are commercially feasible making Hydrogen propulsion as with a Hydrogen piston engine and fuel cell driving for generating power safer because large amounts of Hydrogen do not have to be carried or on hand during use or down times. Replaceable vessels for both Hydrogen generation and Carbon dioxide capture systems provide viable options for both transportation and stationary Hydrogen consumption applications. | 2009-01-15 |
20090016945 | Use of tin phosphates in thermoplastic materials that can be laser-inscribed - A tin phosphate pigment compound with a residual moisture content of a maximum 1% by weight. The compound preferably is a tin orthophosphate with a mean grain fineness of 8 to 20 μm (d | 2009-01-15 |
20090016946 | PROCESS FOR PRODUCING ALUMINUM PHOSPHATE - The present invention provides improved methods for producing the aluminum adjuvant AlPO | 2009-01-15 |
20090016947 | RECYCLING OF HIGH-BOILING COMPOUNDS WITHIN AN INTEGRATED CHLOROSILANE SYSTEM - Trichlorosilane production is increased while simultaneously lowering environmental burden due to destruction and disposition of high boilers by feeding high boilers from trichlorosilane production or from polycrystalline silicon production into a fluidized bed for production of trichlorosilane from metallic silicon and hydrogen chloride. | 2009-01-15 |
20090016948 | Carbon and fuel production from atmospheric CO2 and H2O by artificial photosynthesis and method of operation thereof - The present invention relates generally to reduction of atmospheric carbon dioxide and to production of carbon therefrom for further use as, for example, fuel and morespecifically, to the process of dissolving atmospheric carbon dioxide into a suitable preferably alkali metal salt flux for electrolysis thereof into carbon and oxygen. | 2009-01-15 |
20090016949 | HIGH PURITY SODIUM HYDROGENCARBONATE CRYSTAL PARTICLES AND PROCESS FOR PRODUCING THE SAME - Sodium hydrogencarbonate crystal particles excellent in anti-caking property and anti-thermal decomposition property, and its production process, are provided. | 2009-01-15 |
20090016950 | Terrestrial lightning-powered magnetic organized single crystal diamond blocks: The forces of nature to form the beautiful gem - The new century thrives for the synthesis of larger single crystal diamond blocks for various engineering applications and esthetic marvel. This invention makes use of triggered lightning bolts for instantaneously driving large cross-sections of high electric current density through compresses heated carbonaceous precursor (possibly seeded seed diamond and/or group VIII transition metal catalysts). The said conditions provide huge spin polarized electron motion over large volume for organized magnetization and spin interactions of the lightning bolt with many carbon atoms for the spin induced orbital rehybridization of sp and sp | 2009-01-15 |
20090016951 | DEVICE STRUCTURE OF CARBON FIBERS AND MANUFACTURING METHOD THEREOF - An aggregate structure of carbon fibers, organized by a plurality of carbon fibers, includes, an aggregate of the carbon fibers aligned in a lengthwise direction, in which a density of the carbon fibers at one side end is different from a density of the carbon fibers at the other side end. | 2009-01-15 |
20090016952 | Reducing Ice and Process for Producing Reducing Liquid with Use of the Ice - A reducing ice that after dissolution, exhibits an oxidation-reduction potential of −10 to −2000 mV The pH value after dissolution is preferably ≦9, and the ice can consist of a member selected from among seawater, deionized marine deep water, mineral water, tapwater, purified tapwater, well water, rainwater, tea, coffee and juice. As the reducing ice even after dissolution has an extremely low oxidation-reduction potential, any liquid can be converted to a reducing liquid by addition of the reducing ice thereto. | 2009-01-15 |
20090016953 | High-Temperature Air Braze Filler Materials And Processes For Preparing And Using Same - High-temperature air braze filler materials composed of various ternary metal alloys are described. Noble metals (M) are added as a ternary constituent to a silver-copper oxide (Ag—CuO | 2009-01-15 |
20090016954 | AGGLOMERATION OF ALUMINA AND BINDER THEREFOR - A method for the agglomeration of alumina particles, the method comprising the steps of comminuting a plurality of alumina particles having a soda content of less than approximately 0.4% by weight to a D | 2009-01-15 |
20090016955 | Method of manufacturing artificial zeolite - A method of manufacturing an artificial zeolite. The method includes the steps of: heating a waste insulator to form a molten insulator; quenching and pulverizing the molten insulator; and heat treating the quenched and pulverized insulator in an alkaline aqueous solution. | 2009-01-15 |
20090016956 | Labeled Macrophages and Methods of Use Thereof - Methods of making and using labeled macrophages are described. | 2009-01-15 |
20090016957 | Polypeptides - This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging. | 2009-01-15 |
20090016958 | Nucleoside based proliferation imaging markers - Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation. | 2009-01-15 |
20090016959 | Delivery of antibodies to the central nervous system - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting an antibody or antibody fragment across the blood-brain barrier of an individual and in the treatment and diagnosis of neurological diseases. | 2009-01-15 |
20090016960 | SYSTEM AND METHOD FOR USING GLASS MICROSPHERES CONTAINING A POSITRON-EMITTING ISOTOPE TO IMAGE BLOOD FLOW AND DISTRIBUTE A RADIOMEDICAL TREATMENT SPECIES - A method for imaging the blood flow in a patient receiving radiomedical treatment, including forming a first and a second plurality of generally spherical biologically stable members, with each respective member of the first plurality includes a first non-radioactive isotope distributed substantially uniformly therein that, upon being subjected to an effective amount of neutron irradiation, emits a therapeutic intensity and amount of beta or gamma radiation and wherein each respective member of the second plurality includes a second non-radioactive isotope distributed substantially uniformly therethrough that, upon being subjected to an effective amount of neutron irradiation, emits a detectable intensity and amount of positron radiation. The first and second members are subjected to an effective amount of neutron radiation and the irradiated first and second pluralities of irradiated first and second members are introduced into a patient's circulatory system upstream of a desired treatment site. The second plurality of irradiated members is imaged via positron emission tomography. The second isotope, once activated by neutron irradiation, has a maximum half-life of about four days. | 2009-01-15 |
20090016961 | Stem Cell Fusion Model of Carcinogenesis - Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. | 2009-01-15 |
20090016962 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided are nanostructures comprising a charged outer surface and an inner core comprising a cancer therapeutic agent or imaging agent, wherein the charged outer surface is selectively removable. Further provided are methods of treating subjects having cell proliferative disorders, e.g., cancer, and kits comprising the above nanostructures. | 2009-01-15 |
20090016963 | Genes involved in neurodegenerative conditions - The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate neurodegenerative conditions. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat neurodegenerative conditions. | 2009-01-15 |
20090016964 | HYPERPOLARIZATION METHODS, SYSTEMS AND COMPOSITIONS - The invention provides various methods and systems for providing hyperpolarized materials as well as the hyperpolarized materials so provided. In addition, a method of providing hyperpolarized materials, such as agents, to end users from a remote location is also provided. | 2009-01-15 |
20090016965 | INTERNAL IMAGE ANTIBODIES FOR OPTICAL IMAGING AND THERAPY - Methods using internal image antibodies for photodiagnosis and/or phototherapy. The internal image antibodies are conjugated with a photoactive molecule such as a dye or photosensitizer, to target specific regions, such as biological receptors. The photoactive molecules are then activated for diagnosis or therapy. Advantageously, the internal image antibody is specific for a biological receptor, but does not require isolation of the receptor to prepare the antibody, and provides the desired specificity and selectivity for targeted diagnosis or therapy. | 2009-01-15 |
20090016966 | Air-Freshening Device - A sprayable air-freshening composition comprising active particles for removing malodours, said active particles comprising at least one metal supported on a solid particulate support, wherein the at least one metal is selected from Groups 3 to 12 and the Lanthanide series of the periodic table. | 2009-01-15 |
20090016967 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity. | 2009-01-15 |
20090016968 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF TYPE I DIABETES - A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a fusion protein selected from the group consisting of GLP-1/IgG or variant or fragment thereof and an Ex4/IgG or variant or fragment thereof and an autoimmune suppressor for silencing an autoimmune response against islet beta cells. | 2009-01-15 |
20090016969 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS - The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel. | 2009-01-15 |
20090016970 | CONTINUOUS SPRAY SCALP THERAPY AND DISPENSING SYSTEMS FOR SAME - A spray delivery system in combination with a scalp medication is provided which includes a portable container having a gas imperious container wall, a pressure source disposed within the container, and a selectively operable valve assembly affixed to the container. The scalp medication is in liquid form and is disposed within the container. The scalp medication comprises a hair growth stimulation or hair growth maintenance active ingredient in an amount sufficient to stimulate or maintain hair growth disposed within a pharmacologically acceptable carrier solution. The valve assembly of the system produces a 1 mL spray of said scalp medication within about 5 seconds following a single operation of said valve assembly. A method of treating alopecia using a continuous spray employing such a system is also provided. Both bag-on-valve (bag-in-can) and metered dose packages are disclosed. | 2009-01-15 |
20090016971 | Aqueous fluid photoprotective compositions comprising tertiary-amide-terminated polyamide polymers - Topically applicable, fluid anti-sun/sunscreen compositions useful for protecting the skin and/or the hair against the damaging effects of ultraviolet radiation, contain:
| 2009-01-15 |
20090016972 | Oral cavity care curative and prophylactic composition - The invention relates to stomatology and perfume industry in particular to therapeutic formulation for oral cavity care. The invention refers to oral hygiene means and can be applied for preparation of medical and prophylactic tooth-pastes, gels, liquids for oral care as well as other compositions like chewing gums, jellies, etc. Formulation containing orally applicable active and inert components involves bromelain in amount of 0.01÷1 wt %, xylitol 1.5÷20 wt %. At best bromelain content is 0.1—0.8 wt %, xylitol content—2.2-18 wt %. For attaining remineralizing effect formulation contains anti-carious mineral additive 0.05-3.0 wt % of the list of active components. At best anti-carious mineral additive content is 0.2-2.5 wt %. There are used calcium glycerophosphate and inorganic or organic magnesium salt as anti-carious mineral additive. It is acceptable to use sodium monofluorphosphate, potassium monofluorphosphate, calcium monofluorphosphate or magnesium monofluorphosphate in amount of 0.5-1.5 wt % as anti-carious mineral additive Optimum concentration is 0.8-1.1 wt %. | 2009-01-15 |
20090016973 | Composition and Method for the Prevention of Oral Disease - The discovery of use of stabilized chlorine dioxide at a concentration range of about 0.5% to about 0.9% (w/v) as a composition for the prevention of oral disease through bactericidal and bacteriostatic properties within a microbial environment is disclosed. The bactericidal properties of stabilized chlorine dioxide are further expanded to include kill of an increased number of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in mixed microbial communities. The further discovery of the bacteriostatic properties of stabilized chlorine dioxide present within a microbial environment which inhibit the re-growth rate of oral bacteria after exposure resulting in significant reduction of plaque and oral malodor production is disclosed. The stabilized chlorine dioxide may be in the form of an oral wash or rinse in solution. | 2009-01-15 |
20090016974 | Application of dehydroascorbic acid or derivatives/isomers thereof for artificially coloring the skin - Dehydroascorbic acid and polymeric/monomeric derivatives and isomers thereof are useful for artificially coloring the skin and more particularly as a skin self-tanning agent; the dehydroascorbic acid may be formed “in situ” from ascorbic acid or a derivative or salt thereof via chemical oxidation and/or via enzymatic oxidation, and a two-component agent thereof includes
| 2009-01-15 |
20090016975 | FADE-RESISTANT COLORING COMPOSITION CONTAINING AN ACID DYE AND A CATIONIC CONDITIONING AGENT FOR A KERATIN-CONTAINING SUBSTRATE - The invention relates to a coloring composition for depositing colors to a keratin-containing substrate, said composition comprising: (a) one or more acid dyes; and (b) one or more cationic quaternary ammonium compounds, said quaternary ammonium compound being present in an amount which provides conditioning benefits but which is insufficient to interfere with deposition of said dye on said substrate. | 2009-01-15 |
20090016976 | CITRAL AND CITRONELLAL DERIVATIVES - Improved citral and citronellal derivatives, and fragrance and flavorings including the derivatives, that have a longer useful shelf life than citral and citronellal and/or fragrances and flavoring including citral and citronellal, are disclosed. In particular, the derivatives maintain the fragrance characteristics of citral and citronellal, while lowering the allergic properties, and lemony flavors and fragrances with a longer shelf-life than citral and citronellal, are disclosed. Also discovered are methods of making the derivatives, and articles of manufacture including the derivatives. The derivatives replace the aldehyde group in citral or citronellal with a hydroxy group. In one embodiment, the derivatives also replaced one or more double bonds in citral or the double bond in citronellal with a cyclopropyl group, which can be unsubstituted, or substituted with one or two alkyl, preferably methyl, groups, or with an oxirane or thiirane ring or combinations thereof. The alkyl groups in the cyclopropyl groups can optionally be substituted, for example, with electron donating groups, electron withdrawing groups, groups which increase the hydrophilicity or hydrophobicity, and the like. Examples of suitable articles of manufacture include candles, air fresheners, perfumes, disinfectant compositions, hypochlorite (bleach) compositions, beverages such as beer and soda, denture cleanser tablets and flavored orally-delivered products such as lozenges, candies, and the like. | 2009-01-15 |
20090016977 | DEODORANT COMPOSITIONS AND METHODS FOR MAKING SAME - Deodorant compositions comprising an emulsion including a continuous polar solvent phase and a discontinuous oil phase are provided. The oil phase comprises an oil ingredient and a fragrance material. Methods for making such deodorant compositions are also provided. | 2009-01-15 |
20090016978 | Antiperspirant Compositions - An antiperspirant composition comprising a carrier substance and a water-soluble or water-dispersible thiolated polymer. | 2009-01-15 |
20090016979 | ALUMINUM AND ALUMINUM-ZIRCONIUM COMPOSITIONS OF ENHANCED EFFICACY CONTAINING REDUCED BUFFER AND/OR REDUCED ZIRCONIUM - Basic aluminum chloride (BAC) and aluminum zirconium antiperspirant active of enhanced efficacy are proposed. The acid activated aluminum-zirconium composition having low contents of both glycine and zirconium with Band III/II ration of less than 0.5 is found to provide higher efficacy than the corresponding heat activated aluminum zirconium antiperspirant salt with high HPLC Band III/II ratio and having high contents of both glycine and zirconium at similar M/Cl ratio. | 2009-01-15 |
20090016980 | Method of Pre-Treating Hair Prior to Coloring - The present invention relates to the field of hair coloring. More specifically, the present invention relates to a method of pre-treating hair prior to the application of a hair colorant. The method comprises the steps of applying a pre-treatment composition, comprising a monoalkyl quat, a cellulose thickener, and a quaternary silicone, on all the hair and leaving the pre-treatment composition on the hair, without rinsing it off prior to the application of the colorant. | 2009-01-15 |
20090016981 | THERAPEUTIC COMPOUNDS - A compound having a structure | 2009-01-15 |
20090016982 | COSMETIC COMPOSITION COMPRISING AN ALKYL PHOSPHATE AND A FATTY ALKYL ETHER OF POLYETHYLENE GLYCOL, PROCESSES THEREFOR AND USES THEREOF - Composition containing an aqueous phase and an emulsifying system, where the emulsifying system contains at least one C | 2009-01-15 |
20090016983 | Hair conditioning composition comprising polysaccharide polymer and aminosilicone - Disclosed is a hair conditioning composition comprising: a cationic or nonionic polysaccharide polymer; an aminosilicone; a cationic surfactant; and a high melting point fatty compound. The composition of the present invention can provide hair volume-up benefit and ease-to-rinse feel, while providing improved conditioning benefits. The present invention also relates to a use of the above composition for hair volume-up. | 2009-01-15 |
20090016984 | Drug for Hyperphospheremia and Its Preparative Method - This invention reports a drug for hyperphospheremia and its preparative method. The preparation includes active constituents, lanthanum polystyrene sulfonate, and excipients. The preparative method in the invention can be summarized as follows: Polystyrene sulfonic acid is obtained by treating polystyrene sulfosalt with hydrochloric acid, soaked or eluted with water soluble lanthanum-contained solution, and washed with water till its PH is neutral. Then, the lanthanum polystyrene sulfonate solution is washed till the superfluous La | 2009-01-15 |
20090016985 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY - The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 2009-01-15 |
20090016986 | Cosmetic Composition, a Pharmaceutical Composition and a Process for Preparing Said Compositions - The present invention relates to a cosmetic composition and to a pharmaceutical composition that comprise several agents of topical use and optionally sunscreens. This composition comprises an aqueous medium containing at least one highly polar substance without, however, having the inconveniences noticed in similar compositions of the prior art. These compositions combine the benefits from water-soluble active with the properties of softness and texture that are typical of products that comprise oily-alcoholic, oily or oily-waxy base. Further, the present invention relates to a process for preparing said cosmetic composition and pharmaceutical composition. | 2009-01-15 |
20090016987 | Pharmaceutical composition and therapeutic method - The object of the present invention is, based on the finding of a novel effect of IL-18, to provide pharmaceutical compositions containing IL-18 and therapeutic methods, for preventing, improving, or treating inflammatory diseases such as systemic inflammatory response syndrome (SIRS). Inflammatory diseases, such as SIRS, can be prevented, improved, or treated by administering the pharmaceutical compositions according to the present invention containing IL-18 in an amount which does not bring the decreased interleukin 18 level in either plasma or liver to a higher level than normal. | 2009-01-15 |
20090016988 | Modified Pore-Forming Protein Toxins and Use Thereof - The present invention provides modified pore-forming protein toxins (MPPTs), capable of being used to kill cancer cells. The MPPTs according to the present invention comprise a modification of the naturally occurring activation sequence comprising one or more general cleavage sites, each of which is cleavable by general activating agent, or a plurality of specific cleavage sites, each of which is cleavable by a specific activating agent. Optional further modifications that allow specific targeting of these molecules are also described. These MPPTs may be used to treat cancer. | 2009-01-15 |
20090016989 | ANTIBODIES TO HUMAN SOMATOSTATIN RECEPTOR AND METHODS OF USE - The invention provides isolated antibodies, including monoclonal and polyclonal antibodies, and the antigen-binding portions thereof, that specifically bind to the extracellular loop 2 (ecl2) of human somatostatin receptor (hSSTR) subtype 1, 2, 3, 4, or 5. The antibodies and antigen-binding portions of the present invention can possess hSSTR agonist-like and/or antagonist-like properties. The invention further provides methods of making the antibodies and antigen-binding portions thereof, and methods of using the antibodies and antigen-binding portions for diagnosing and treating various indications, including cancer and carcinoid syndrome. | 2009-01-15 |
20090016990 | Antimicrobial Compositions - The present invention relates in part to a composition comprising a compound of Formula I or Formula II and at least one other antimicrobial agent. The invention also relates in part to a pharmaceutical composition comprising the composition of claim | 2009-01-15 |
20090016991 | Rxr Antagonist Treatment Against Multiple Sclerosis - Retinoids with retinoid antagonistic activities, especially Retinoid X Receptor antagonists called RXR antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable esters and amides thereof, have been found to be effective in the treatment of multiple sclerosis, especially by systemic such as oral administration of RXR antagonists. | 2009-01-15 |
20090016992 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2009-01-15 |
20090016993 | MEDICINAL FORMULATION FOR THE TREATMENT FOR HEPATITIS C - A composition for the treatment of Hepatitis C infection is disclosed. The composition comprises a homogenized mixture of at least one serially diluted and potentized substance, as herein described, selected from: Hepatitis C Genotype 1, Hepatitis C Genotype 2, Hepatitis C Genotype 3, Hepatitis C Genotype 4, Hepatitis C Genotype 5, Hepatitis C Genotype 6 along with a vehicle selected from a group consisting of normal saline, distilled water and ethyl alcohol (90 to 100%). A process for making the composition is also disclosed. | 2009-01-15 |
20090016994 | Preparation of fibroblast-populated connective tissue substitute - Disclosed is a method for in vitro growing of connective tissue substitute, said connective tissue substitute being populated with fibroblasts, a connective tissue substitute obtainable by such a method, as well as a method for closing of a wound, wherein such connective tissue substitute is applied onto a wound. | 2009-01-15 |
20090016995 | Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease - A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro. | 2009-01-15 |
20090016996 | HAIR MESENCHYMAL CELLS - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect. | 2009-01-15 |
20090016997 | Autologous/allogeneic human DNA grafting, anti-and reverse aging stem cell, and bone marrow compositions/methods - Anti-aging compositions and methods for delivering (engrafting) younger compatible human DNA to tissues, through the systematic periodic introduction of younger primordial whole (nucleated) stem cells and bone marrow into a recipient, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions are disclosed. | 2009-01-15 |
20090016998 | NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES - A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease. | 2009-01-15 |
20090016999 | Embryonic cell compositions for wound treatment - Compositions including formulations comprising stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Methods for using the compositions and formulations for enhancing would healing are also provided. Wounds to both soft and bony tissues are encompassed, and include wounds created by surgical procedures. | 2009-01-15 |
20090017000 | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies - Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation. | 2009-01-15 |
20090017001 | AMBIENT STORED BLOOD PLASMA EXPANDERS - A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of; or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described. | 2009-01-15 |
20090017002 | PREVENTION AND TREATMENT OF OXIDATIVE STRESS DISORDERS BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES - The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. | 2009-01-15 |
20090017003 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS - The present invention relates to novel thiosulfonates derivatives. The present invention also provides methods for preventing, treating and/or reducing inflammation-associated diseases in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous or cutaneous systems as well as infective and tumoral diseases employing said compounds. | 2009-01-15 |
20090017004 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID - The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 2009-01-15 |
20090017005 | Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders. | 2009-01-15 |
20090017006 | USE OF A COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE - The present invention is directed to the use of Bortezomib and/or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2. | 2009-01-15 |
20090017007 | LIQUID FACTOR VII COMPOSITION - Storage-stable aqueous pharmaceutical compositions comprising a Factor VII or Factor Vila polypeptide, a buffering agent, and zinc ions (Zn | 2009-01-15 |
20090017008 | Compositions and methods for altering bone density and bone patterning - By exploiting cross-species sequence comparisons with in vitro and in vivo enhancer assays we were able to identify enhancer elements that drives human SOST expression in the adult mouse skeleton, and discovered a novel function for sclerostin during limb development. The enhancer elements and reagents described in the present invention facilitate the methods for development of products and methods to increase the mineral content of bone, which can consequently be utilized to treat a wide variety of bone related conditions, including, osteopenia, osteoporosis, fractures and other disorders in which low bone mineral density are the main cause of the disease as well as sclerosteosis, Van Buchem disease and other related disorders of the skeleton. Furthermore, the present invention provides enhancer elements and reagents useful for bone pattering and growth, limb development, and the formation of individual bones | 2009-01-15 |
20090017009 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 2009-01-15 |
20090017010 | NOVEL ARTEMIS/DNA-DEPENDENT PROTEIN KINASE COMPLEX AND METHODS OF USE THEREOF - In the present invention, it is disclosed that Artemis forms a complex with the 469 kDa DNA-dependent protein kinase (DNA-PK | 2009-01-15 |
20090017011 | MODULATION OF VEGF-C/VEGFR-3 INTERACTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to methods for treating an individual exhibiting symptoms of chronic arthridites, as identified by an elevated level of VEGF-C expression at synovial sites, and provides materials and methods for the modulation of VEGF-C/VEGFR-3 ligand-receptor interactions as a treatment for chronic arthridites. | 2009-01-15 |
20090017012 | METHODS OF DIAGNOSING AND TREATING CANCER - The invention relates to methods of determining an appropriate cancer therapy for a subject based on intratumoral expression levels of Ribonucleotide Reductase M1 (RRM1) and thymidylate synthase (TS) gene expression, as well as to methods of predicting clinical outcome (prognosis) based on cytoplasmic levels of TS protein. Compositions and kits useful for the methods are also provided. | 2009-01-15 |
20090017013 | MOLECULES FOR THE TREATMENT OF LUNG DISEASE INVOLVING AN IMMUNE REACTION TO CONNECTIVE TISSUE FOUND IN THE LUNG - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 2009-01-15 |
20090017014 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-01-15 |
20090017015 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders - The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability. | 2009-01-15 |
20090017016 | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy - The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule. | 2009-01-15 |
20090017017 | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture - The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immonoglobulin products. | 2009-01-15 |
20090017018 | USES OF MAMMALIAN CYTOKINE: RELATED REAGENTS - Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders. | 2009-01-15 |
20090017019 | METHODS AND COMPOSITIONS FOR MODULATING BMP-10 ACTIVITY - Methods and compositions for modulating cardiac, renal and vascular cell function and homeostasis using agonists and antagonists of BMP-10 are disclosed. In particular, methods for treating, preventing and/or diagnosing BMP-10-associated vascular, renal, fibrotic and cardiac conditions and/or disorders are disclosed. Screening methods for evaluating BMP-10 modulators, e.g., agonists and antagonists, are also disclosed. | 2009-01-15 |
20090017020 | RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS - Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. | 2009-01-15 |
20090017021 | Methods and compositions for inducing innate immune responses - The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity. | 2009-01-15 |
20090017022 | SULFATASES AND METHODS OF USE THEREOF - Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase. | 2009-01-15 |
20090017023 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2009-01-15 |
20090017024 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders - Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject. | 2009-01-15 |
20090017025 | Combinations Comprising a CDK Inhibitor and a Growth Factor Antibody or Anti-Mitotic - The present invention provides a combination comprising a compound A of formula (I) as set forth in the specification or a pharmaceutically acceptable salt thereof, and an antibody inhibiting a growth factor or its receptor and/or an antimitotic agent or a derivative or prodrug thereof, useful in the treatment of tumors. The chemical name of compound A is 8-[4-(4-methyl-piper-azin-1-yl)-phenylamino]-1,4,4-trimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid methylamide. | 2009-01-15 |
20090017026 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2009-01-15 |
20090017027 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2009-01-15 |
20090017028 | ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. | 2009-01-15 |
20090017029 | Methods and Compositions for Treating Ocular Disorders - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis or AMD. | 2009-01-15 |
20090017030 | Endothelial Cell Expression Patterns - To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 2009-01-15 |
20090017031 | METHODS FOR PREVENTING AND TREATING TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA-REPERFUSION INJURY - A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved in the formation of the membrane attach complex, preferably antibodies that inhibit MBL, MASP1, MASP2, and MASP3 in the lectin pathway. The complement inhibitors can be used alone or in combination to decrease the morbidity and mortality caused by tissue damage associated with ischemia-reperfusion injury or TAAA repair. | 2009-01-15 |
20090017032 | MAMMALIAN CX3C CHEMOKINE ANTIBODIES - Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2009-01-15 |
20090017033 | Methods for interfering with RANKL signaling - Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL. | 2009-01-15 |
20090017034 | Antibodies that inhibit TSLP activity - The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. | 2009-01-15 |
20090017035 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon resonance. | 2009-01-15 |
20090017036 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS - The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK | 2009-01-15 |
20090017037 | Human TIMP-1 Antibodies - Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis. | 2009-01-15 |
20090017038 | Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods - The present invention relates to the identification, isolation and characterization of the proteins forming the sigma-2 receptor. The invention further relates to the utilization of said proteins for preparing a screening for the sigma-2 receptor, as well as assay of specific candidate ligands to the use of the ligands for setting up diagnostic assays for tumour tissues and for preparing antitumour drugs. Lastly, the isolated proteins are utilized for producing anti-receptor antibodies, which likewise find employ in the diagnosis and therapeutic treatment of neoplasias. | 2009-01-15 |
20090017039 | SP35 Antibodies and uses thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody | 2009-01-15 |
20090017040 | Monoclonal antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD) | 2009-01-15 |